NCT05779592Active, not recruiting
A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
An Observational Study Evaluating Treatment Situations of Adjuvant Nivolumab for Muscle-invasive Urothelial Carcinoma in Japan
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the effectiveness, safety, and actual treatment status of nivolumab administered as an adjuvant treatment for participants with muscle-invasive urothelial carcinoma (MIUC), including bladder, renal pelvis, and ureteral cancer, in a Japanese real-world clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 24 Feb 2023
- Start date
- 23 Nov 2022
- Primary completion date
- 2 Jan 2029
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Bladder cancer
- NCT number
- NCT05779592
What you commit to
- Study type: Observational
- Planned participants: 400
- From 23 Nov 2022 to the primary completion date, 2 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who underwent only partial resection for MIUC
- Participants treated with chemotherapy, radiotherapy, biologics (anticancer agents), intravesical chemotherapy, or Bacillus Calmette-Guérin therapy from the time of radical resection of MIUC to the start of nivolumab
- Participants previously treated with immune checkpoint inhibitors prior to nivolumab treatment
- Other protocol-specific inclusion/exclusion criteria apply.
Who the study is looking for
- Must have a histologically definitive diagnosis of MIUC at each study site and who must have received nivolumab after radical resection
- Must present at least once to the study site after nivolumab treatment or must have survival data
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Local Institution Coordinator of this site? Confirm its status | City | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.